Studying how fat tissue affects liver fat in type 1 diabetes
Tests scans, meal tests and fat tracers in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: How Abnormal Function of Fat Tissue in Type 1 Diabetes Contributes to Fat in the Liver
Key facts
- Where
- Sherbrooke, CanadaSee the site
Where in Canada
- Centre de recherche du CHUSSherbrooke, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Université de Sherbrooke
- Trial code
- NCT07133854
- Record updated
- 21 August 2025
- Original description
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.Read full original descriptionShow less
The Impact of Adipose Tissue Insulin Resistance and Abdominal Obesity on Hepatic Fatty Acid Metabolism in Type 1 Diabetes
Steatotic liver disease associated with metabolic dysfunction (MASLD) is a disease caused by excess fat storage in the liver. Excessive fat delivery to the liver and MASLD typically occurs in people with abdominal obesity and type 2 diabetes. Type 1 diabetes (T1D) is also associated with a marked increase in the release of fat from adipose tissues and MASLD is increased in T1D and significantly increases the risk of heart, kidney and eye diseases.
Inclusion: 16 individuals living with T1D and abdominal obesity, as defined by the International Diabetes Federation country/ethnic group-specific criteria (https://www.idf.org/e-library/consensus-statements/60- [1]. Treatment for T1D will be intensive insulin therapy on continuous pump perfusion with continuous glucose monitoring; 16 individuals with normoglycemia (i.e., HbA1c below 6.0%) matched for sex, age (± 5 years), waist circumference (± 3 cm), and menopausal status.
Exclusion: use of any medication other than insulin that may affect lipid or carbohydrate metabolism and that cannot be stopped prior to testing; Having participated to a research study with exposure to radiation in the last year before the start of the study; presence of overt cardiovascular, liver or renal disease (except microalbuminuria without reduced kidney function), or other uncontrolled medical conditions; Being allergic to eggs; history of primary dyslipidemia (LDL-cholesterol over 5 mmol/L or TG over 10 mmol/L) or uncontrolled high blood pressure (over 160/100 mmHg) precluding the withdrawal of lipid lowering and anti-hypertensive agents as per protocol; less than 70% of time in glycemic range (for T1D); current or planned pregnancy within the next 6 months; any contraindication to MRI; Smoking (>1 cigarette/day) and/or consumption of >2 alcoholic beverages per day.